Clinical Trial Update: Proteome-based Personalized Immunotherapy of Glioblastoma [Phase 2, Phase 3]

View source ↗

Summary

This document notes an ongoing Phase 2/Phase 3 trial of proteome-based personalized immunotherapy for glioblastoma, with the current status unspecified.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma

Drugs mentioned

• Proteome-based Personalized Immunotherapy

Snippet

Sponsor: NeuroVita Clinic | Conditions: Glioblastoma | Phase 2, Phase 3 | Status: UNKNOWN